Time-Limited Triplet Therapy Induces Rapid Undetectable MRD Responses in CLL

Zanubrutinib, obinutuzumab, and venetoclax (BOVen), given on a treatment schedule driven by minimal residual disease milestones, is a promising approach to previously untreated chronic lymphocytic leukemia, according to new findings from an investigator‐initiated phase II study.